|
C3ORF34 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.44089209850063E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62558855265615E-12 |
| Normal-vs-Stage2 |
9.8792000136072E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
9.275900E-02 |
| Stage1-vs-Stage3 |
1.343800E-01 |
| Stage1-vs-Stage4 |
2.750000E-02 |
| Stage2-vs-Stage3 |
1.348470E-02 |
| Stage2-vs-Stage4 |
3.677800E-03 |
| Stage3-vs-Stage4 |
3.972600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
2.30426788760951E-12 |
| Normal-vs-Asian |
2.75150002781999E-09 |
| Caucasian-vs-AfricanAmerican |
6.293400E-01 |
| Caucasian-vs-Asian |
6.923000E-03 |
| AfricanAmerican-vs-Asian |
4.431600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
5.55111512312578E-16 |
| Male-vs-Female |
8.536400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.6251444634463E-12 |
| Normal-vs-Age(81-100Yrs) |
3.04979999998789E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.525800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.089600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.427800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.175600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.728400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.500000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.117560E-02 |
| Classical-VS-Follicular |
5.619600E-01 |
| Classical-VS-Other |
6.520400E-01 |
| Classical-VS-Normal |
8.99280649946377E-15 |
| Tall-VS-Follicular |
1.020270E-02 |
| Tall-VS-Other |
6.869000E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
5.428000E-01 |
| Follicular-VS-Normal |
1.62547753035369E-12 |
| Other-VS-Normal |
1.572530E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.270170E-02 |
|
|
